Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTAK vs STXS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STXS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 4–6 Matrix Metrics)

STXS Overall Winner 6-Pillar Tally: VTAK 0 – 5 STXS (1 Tie) Matrix Metrics: VTAK 6 – 4 STXS

As of Nov 16, 2026, Stereotaxis, Inc. (STXS) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas STXS carries 49.3/100 (HOLD) at $0.80 (19.6x Forward P/E, -65.0% operating margin).

  • Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. STXS 49.3/100 HOLD), STXS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-65.0% vs. -388.1% operating margin) and revenue trajectory (+19.6% vs. +380.7% YoY).
  • Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile STXS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTAK vs STXS
VTAK NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21
STXS NYSE American Head-to-Head Winner
Stereotaxis, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$0.80
-4.8% 1D
Market Cap $85.0M
TTM Revenue $32M
Forward P/E 19.6x
Beta / 30D Vol 1.11β · 97% Vol
Unified Composite Score
49.3 / 100 HOLD
Tech 56.0 Fund 64.0 Flow 59.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.0%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.96 · SMA50: $1.12

6-Pillar Scorecard Institutional Category Breakdown (VTAK 0 – 5 STXS)

Columns: Metric · VTAK · STXS
1. Valuation Multiples STXS
Forward P/E N/M 19.6x
Trailing P/E N/M 19.6x
PEG Ratio N/M 1.31x
EV / Revenue 0.3x 2.4x
2. Growth & Scale STXS
Revenue Growth (YoY) +380.7% +19.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.9M $32M
Market Cap $548,639 $85.0M
3. Profitability & Quality STXS
Gross Margin 47.7% 52.5%
Operating Margin -388.1% -65.0%
Net Profit Margin 0.0% -70.9%
Return on Equity (ROE) -111.3% -117.4%
4. Balance Sheet & Cash Flow STXS
Cash Generation (TTM) -$10M EBITDA -$16M
Cash Flow Margin N/A -49.2%
Net Cash / Leverage $4.87 Book/Sh · -111.3% ROE $9.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STXS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 62.8% (18th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTAK (6) vs STXS (4)
Institutional Metric VTAK STXS Criterion Row Edge
Market Capitalization
Scale
$548,639 $85.0M Larger Scale STXS
Trailing P/E Ratio
Valuation
N/M 19.6x Lower Multiple STXS
Forward P/E Ratio
Valuation
N/M 19.6x Lower Multiple STXS
Revenue Growth (YoY)
Growth
+380.7% +19.6% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-388.1% -65.0% Higher Margin STXS
Net Profit Margin
Profitability
0.0% -70.9% Higher Margin VTAK
Return on Equity (ROE)
Capital Efficiency
-111.3% -117.4% Higher ROE VTAK
52-Week Range Position
Momentum
1% ($0–$3) 0% ($1–$3) Stronger Trend VTAK
Beta / 30D Volatility
Risk Regime
0.19β · 76% Vol 1.11β · 97% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 49.3 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$1.9M $32M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.7% 52.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev 1.31x PEG · 2.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) -$16M ($9.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STXS +10.27 pp
VTAK: -24.76% · STXS: -14.49%
3M Horizon STXS +42.72 pp
VTAK: -80.29% · STXS: -37.57%
6M Horizon STXS +46.86 pp
VTAK: -83.76% · STXS: -36.9%
1Y Horizon STXS +45.31 pp
VTAK: -92.63% · STXS: -47.32%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VTAK Revenue STXS Revenue VTAK Op. Margin STXS Op. Margin Margin Leader
FY2018 $10M $30M -498.0% -8.4% STXS
FY2019 $10M $30M -801.9% -16.7% STXS
FY2020 $0M $30M -13668.3% -25.2% STXS
FY2021 $0M $40M -133027.3% -36.8% STXS
FY2022 $0M $30M -192578.6% -66.7% STXS
FY2023 $0M $30M -17674.0% -81.6% STXS
FY2024 $0M $30M -2676.9% -91.9% STXS
FY2025 $0M $30M -2581.6% -68.3% STXS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STXS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 62.8%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STXS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STXS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $85.0M market capitalization and -65.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTAK vs STXS Key Questions & Quantitative Answers

As of Nov 16, 2026, Stereotaxis, Inc. (STXS) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas STXS carries 49.3/100 (HOLD) at $0.80 (19.6x Forward P/E, -65.0% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. STXS 49.3/100 HOLD), STXS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-65.0% vs. -388.1% operating margin) and revenue trajectory (+19.6% vs. +380.7% YoY). Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile STXS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STXS leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with STXS at +19.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (52.5% gross margin, -65.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTAK cumulative revenue shifted +0.0% while STXS shifted +0.0%. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STXS.

STXS screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas STXS trades at 19.6x Forward P/E, 19.6x Trailing P/E, 1.31x PEG, and 2.4x EV/Revenue (-49.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus STXS (-117.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, STXS carries 62.8% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.